22:01
Targeting SARM1 and Axon Degeneration as a Design-Modifying Strategy for the Treatment of CMT2A
53:57
Keynote: From Genes to Treatments: Strategic Considerations for CMT Therapy Development
57:44
Neurology | Upper Motor Neuron vs Lower Motor Neuron Lesion | UMN vs LMN Lesion
25:11
ToPIC: Building a CMT Guidance Document for the FDA
24:03